Literature DB >> 18044763

An evaluation of octogenarians undergoing percutaneous coronary intervention from the Melbourne Interventional Group registry.

Bryan P Yan1, Ronen Gurvitch, Stephen J Duffy, David J Clark, Martin Sebastian, Gishel New, Roderick Warren, Jeffery Lefkovits, Robert Lew, Angela L Brennan, Chris Reid, Nick Andrianopoulos, Andrew E Ajani.   

Abstract

OBJECTIVES: The objective of this study was to evaluate the clinical characteristics and outcomes of octogenarians (> or =80 years of age) in a contemporary, multi-centre percutaneous coronary intervention (PCI) registry.
BACKGROUND: Octogenarians are increasingly referred for PCI. This patient population frequently has significant comorbidities, which result in major therapeutic challenges.
METHODS: The study population consisted of consecutive patients undergoing PCI in seven major Australian hospitals, who were treated over a 2-year period (2004-2005).
RESULTS: Of 4,360 PCI's, 11.3% (n = 491) were performed in octogenarians and 88.7% (n = 3,869) in patients <80 years. Octogenarians (compared with patients <80 years of age) were more likely female and have greater comorbidities such as cerebrovascular disease, renal impairment, congestive heart failure, and chronic airway disease. Octogenarians more frequently presented with acute coronary syndromes and cardiogenic shock. Octogenarians had significantly increased 30-day (6.0 vs. 1.4%, P < 0.01) and 12-month mortality (8.4% vs. 2.5%, P < 0.01), and major adverse cardiac event rates [(MACE), 30 days 11.3% vs. 5.4%, P < 0.01 and 12-months 18.7% vs. 12.9%, P = 0.04]. Cardiogenic shock, ST-segment elevation myocardial infarction, chronic renal failure, and age > or =80 years were independent predictors of 12-month mortality.
CONCLUSIONS: Octogenarians comprise a significant cohort of patients undergoing PCI. Octogenarians have more comorbidities, and higher rates of mortality and MACE, mandating thorough clinical evaluation before acceptance for PCI. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 18044763     DOI: 10.1002/ccd.21303

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  6 in total

1.  PCI comes to age as age increasingly comes to PCI.

Authors:  J Waltenberger; J Vainer
Journal:  Neth Heart J       Date:  2008-04       Impact factor: 2.380

2.  Interventional treatment and outcome in elderly patients with stable coronary artery disease. Results from the German ALKK registry.

Authors:  H Rittger; M Hochadel; S Behrens; K E Hauptmann; R Zahn; H Mudra; J Brachmann; U Zeymer
Journal:  Herz       Date:  2013-05-29       Impact factor: 1.443

3.  Intra-arterial recanalization techniques for patients 80 years or older with acute ischemic stroke: pooled analysis from 4 prospective studies.

Authors:  A I Qureshi; M F K Suri; A L Georgiadis; G Vazquez; N A Janjua
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-02       Impact factor: 3.825

4.  Effectiveness of percutaneous coronary intervention within 12 hours to 28 days of ST-elevation myocardial infarction in a real-world Chinese population.

Authors:  Xingli Wu; Dingyou Yang; Yusheng Zhao; Caiyi Lu; Yu Wang
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

5.  Success rate, procedural complications and clinical outcomes of coronary interventions in octogenarians: a case-control study.

Authors:  Hamidreza Poorhosseini; Mehdi Mousavi; Ebrahim Nematipour; Seyed Ebrahim Kassaian; Mojtaba Salarifar; Mohammad Alidoosti; Alimohammad Hajizeinali; Younes Nozari; Alireza Amirzadegan; Seyed Kianoosh Hosseini; Mahmood Sheikhfathollahi
Journal:  J Tehran Heart Cent       Date:  2011-08-31

6.  Acute coronary syndrome in octogenarians: association between percutaneous coronary intervention and long-term mortality.

Authors:  Salim Bary Barywani; Shijun Li; Maria Lindh; Josefin Ekelund; Max Petzold; Per Albertsson; Lars H Lund; Michael Lx Fu
Journal:  Clin Interv Aging       Date:  2015-09-28       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.